Who signed the Akari Therapeutics (AKTX) 8-K related to the investor presentation?

The report was signed on behalf of Akari Therapeutics, Plc by Torsten Hombeck, the company’s Chief Financial Officer.

Akari Therapeutics posts updated investor presentation

Q: How will Akari Therapeutics (AKTX) use the updated investor presentation?

Representatives of Akari Therapeutics plan to use the updated investor presentation in various meetings with investors and other parties from time to time.

Q: Can the Akari Therapeutics (AKTX) investor presentation be incorporated into other SEC filings?

It will only be incorporated into other Securities Act or Exchange Act filings if those future filings expressly include it by specific reference.

Q: Which exhibit contains the Akari Therapeutics (AKTX) corporate presentation?

The updated corporate investor presentation is included as Exhibit 99.1 to the current report.

Akari Therapeutics, Plc filed a current report to let investors know it has released an updated corporate investor presentation.

Accepted by SEC EDGAR 08/19/2025 - 08:00 AM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Akari Therapeutics, Plc filed a current report to let investors know it has released an updated corporate investor presentation. The company states that this updated presentation, attached as Exhibit 99.1, will be used by its representatives in various meetings with investors and other stakeholders from time to time.

The information in this presentation is furnished under a Regulation FD disclosure, meaning it is intended to provide broad, fair disclosure but is not treated as filed for liability purposes under the Exchange Act. Akari also notes that the materials will only be incorporated into other securities law filings if specifically referenced in those future documents.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Akari Therapeutics (AKTX) disclose in this 8-K filing?

Akari Therapeutics disclosed that it made an updated investor presentation available and furnished it as Exhibit 99.1 for use in various meetings.

How will Akari Therapeutics (AKTX) use the updated investor presentation?

Representatives of Akari Therapeutics plan to use the updated investor presentation in various meetings with investors and other parties from time to time.

Is the Akari Therapeutics (AKTX) investor presentation considered filed with the SEC?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act.

Can the Akari Therapeutics (AKTX) investor presentation be incorporated into other SEC filings?

It will only be incorporated into other Securities Act or Exchange Act filings if those future filings expressly include it by specific reference.

Which exhibit contains the Akari Therapeutics (AKTX) corporate presentation?

The updated corporate investor presentation is included as Exhibit 99.1 to the current report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

Akari Therapeutics, Plc

(Exact Name of Registrant as Specified in Charter)

England and Wales

001-36288

98-1034922

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

22 Boston Wharf Road FL 7

Boston, MA 02210

(Address, including zip code, of Principal Executive Offices)

Registrant’s telephone number, including area code: (929) 274-7510

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol(s)

Name of each

exchange on which registered

American Depositary Shares, each representing 2,000 Ordinary Shares

AKTX

The Nasdaq Capital Market

Ordinary Shares, par value $0.0001 per share*

*Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 19, 2025, Akari Therapeutics, Plc (the “Company”) made available an updated investor presentation, a copy of which is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings from time to time.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Akari Therapeutics, Plc

Date: August 19, 2025	By:	/s/ Torsten Hombeck
		Torsten Hombeck
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR